New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

MONJUVI (tafasitamab-cxix) for injection. FDA-Approved. To treat lymphoma

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

MONJUVI (tafasitamab-cxix) for injection is a prescription medicine. MONJUVI (tafasitamab-cxix) for injection is used to treat odiffuse large B-cell lymphoma (DLBCL).
MONJUVI is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified,
including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
For injection: 200 mg of tafasitamab-cxix as lyophilized powder in singledose vial for reconstitution.
Manufactured By: MORPHOSYS US INC
Prescribing Information URL: Click Here

South Delhi Pharma facilitate the supply of “NURTEC ODT (rimegepant) FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.

Categories ,
Categories ,

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite.

Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.

Tafasitamab was approved for medical use in the United States in July 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Related Products